Gastric cancer often portends a very dismal prognosis, particularly in the immune-cold type of tumor, including HER2 negativity, PD-L1 CPS <1, microsatellite stability, and low tumor mutational burden (6, 8). This evidence concerns the gene ERBB2 and neoplasm.